Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 3/2011

01-09-2011 | Clinical Trial Report

Is Two Better Than One? Combining Antiresorptive and Anabolic Osteoporosis Medications

Authors: Nicole C. Wright, Kenneth G. Saag

Published in: Current Osteoporosis Reports | Issue 3/2011

Login to get access

Excerpt

Trial: Cosman F, Eriksen EF, Recknor C, et al.: Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. J Bone Miner Res 2011, 26(3):503–511. …
Literature
1.
Boonen S, Marin F, Obermayer-Pietsch B, Simoes ME, Barker C, Glass EV, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008;93(3):852–60.PubMedCrossRef
2.
Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005;353(6):566–75.PubMedCrossRef
3.
Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004;19(5):745–51.PubMedCrossRef
4.
Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008;93(10):3785–93.PubMedCrossRef
5.
Gasser JA, Kneissel M, Thomsen JS, Mosekilde L. PTH and interactions with bisphosphonates. J Musculoskelet Neuronal Interact. 2000;1(1):53–6.PubMed
6.
Foster S, Foley K, Meadows E, Johnston J, Wang S, Pohl G, et al. Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. Osteoporos Int. 2011;22(2):551–7.PubMedCrossRef
Metadata
Title
Is Two Better Than One? Combining Antiresorptive and Anabolic Osteoporosis Medications
Authors
Nicole C. Wright
Kenneth G. Saag
Publication date
01-09-2011
Publisher
Current Science Inc.
Published in
Current Osteoporosis Reports / Issue 3/2011
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-011-0057-0

Other articles of this Issue 3/2011

Current Osteoporosis Reports 3/2011 Go to the issue

ReviewPaper

A Review of Osteoporosis Diagnosis and Treatment Options in New and Recently Updated Guidelines on Case Finding Around the World

ReviewPaper

Osteoporosis: A Paradox in Ankylosing Spondylitis

ReviewPaper

The Role of Risk Communication in the Care of Osteoporosis

ReviewPaper

Diagnostic Thresholds in Osteoporosis: How Are They Used in Clinical Trials?

ReviewPaper

Osteopenia: A Diagnostic and Therapeutic Challenge

ReviewPaper

Choosing a Treatment for Patients at the Time a Fracture is Presented